Please assess the completion status of the following clinical trial:

Trial Title: Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients of ≥18 years at time of informed consent~2. Patients with a clinical diagnosis of CF and confirmed by genetic testing~3. Diagnosis of treatment naïve or treatment refractory M. abscessus-PD~4. Signed informed consent documentation (indicating an understanding of the purpose and a willingness to meet the requirements for participation in the study)~Exclusion Criteria:~1. FEV1 \<40% predicted~2. Methaemoglobin concentration \> 2%~3. Use of nitric oxide donor medications such as prilocaine, sodium nitroprusside, and nitroglycerine within 30 days of proposed first treatment~4. Use of phosphodiesterase inhibitors (e.g., sildenafil) within 30 days of proposed first treatment~5. Evidence of pulmonary hypertension~6. History of frequent low volume or massive haemoptysis~7. Liver disease (i.e. liver cirrhosis, portal hypertension)~8. Subjects who have undergone organ transplantation~9. Pregnancy or lactation (female participants only)~10. Subjects who will not use appropriate forms of contraception for the duration of the study~11. Contraindication or unable to complete lung function testing~12. Contraindication or unable to tolerate nebulised hypertonic saline~13. Changes to previous NTM antibiotic regimen within two months of first dose of study treatment (or 4 months for clofazimine)~14. Subject has received investigational treatment as part of another interventional clinical trial within two months of the proposed first day of treatment~15. Required antibiotic treatment for a pulmonary exacerbation within 2 weeks of enrolment to the study.~16. Inability to undergo study related activities and / or commitments~17. Any subject who in the opinion of the investigator would not be best served by participating in this clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interventional (Type: EXPERIMENTAL): Single arm trial involving all patients receiving IMP

Based on this trial design, predict the completion outcome and termination type (if applicable).